2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 15, 2015
- Pharmaceutical Technology-03-15-2015
- Volume 2015 eBook
- Issue 1
Assessing and Improving the Palatability of Pharmaceuticals
Taste may be subjective, but it is crucial to patient compliance, particularly for pediatric treatments.
Advertisement
Taste may be subjective, but it is crucial to patient compliance, particularly for pediatric treatments. This article reviews methods used to improve and assess pharmaceutical palatability.
Articles in this issue
over 11 years ago
Advances in Tabletingover 11 years ago
Analytical Techniques for Oral Solid Dosage Formulationover 11 years ago
Simplify Formulation With PATover 11 years ago
Boosting Solubility in Lipid-Based Formulationsover 11 years ago
Innovations in Solid Dosage EquipmentAdvertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Advertisement
Advertisement